On the other hand, IDH1 mutations, a key molecular feature of astrocytomas and oligodendrogliomas, correlate with better prognosis, longer survival, and increased treatment response, particularly to temozolomide [27]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).